Nurix (NRIX) CFO Hans van Houte Sells Shares

What Happened
Hans van Houte, Chief Financial Officer of Nurix Therapeutics (NRIX), sold a total of 4,761 shares in two open-market transactions on August 4, 2026. The first block was 1,794 shares at a weighted average price of $23.89 (proceeds $42,861) and the second was 2,967 shares at a weighted average price of $24.65 (proceeds $73,129), for aggregate proceeds of $115,990. These were sales (not purchases) and were effected under a pre-existing Rule 10b5-1 trading plan.

Key Details

• Transaction dates: 2026-08-04 (both sales)
• Prices and amounts: 1,794 shares @ $23.89 = $42,861; 2,967 shares @ $24.65 = $73,129; total 4,761 shares, ~$115,990
• Reported price ranges: first sale lowest $23.42 / highest $24.39 (F2); second sale lowest $24.42 / highest $24.83 (F3). The filing gives weighted averages; the insider can provide a per-price breakdown on request.
• Footnote: F1 indicates these trades were made under a Rule 10b5-1 plan (pre-arranged trading plan).
• Shares owned after transaction: not specified in the provided filing.
• Filing timeliness: Report filed same day as the transactions (period of report and filing date 2026-08-04), so no late filing indicated.

Context
Sales under a 10b5-1 plan are pre-scheduled and are generally considered routine disposition rather than an immediate signal of insider sentiment. This report documents disposition of existing holdings rather than an acquisition or option exercise.